ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Phase 3 failure of asthma therapy sends Vectura's ailing shares falling
November 28, 2018Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, after it failed in Phase 3 trials to demonstrate... -
Vectura pulls the plug on experimental asthma therapy
November 28, 2018Vectura says it no longer plans to develop and partner experimental asthma therapy VR475, after it failed to hit Phase III targets. -
Vectura takes £40 million hit as asthma drug fails trial
November 28, 2018Vectura has abandoned a late-stage drug in severe uncontrolled asthma after it failed a phase 3 trial, resulting in a decline in its already-depressed share price.
Pharma Sources Insight January 2025
